J&J marketing spend falls, but Olysio fuels a sales hike

Share this article:
J&J to submit schizophrenia drug in 2014
J&J marketing spend falls, but Olysio fuels a sales hike

Johnson & Johnson saw pharmaceutical sales jump 7.7% in the US during the first quarter, and more than 12% worldwide, compared to the same period last year. The $7.5 million in pharmaceutical sales is also of note, because this bump is accompanied by a lower quarterly investment in marketing and selling expenses. Spending in this category, which also includes administrative expenses, was down 0.8% compared to the same period last year.

Fueling the pharmaceutical sales rise has been hepatitis C drug Olysio, which the FDA approved in November. The drug's launch went better than expected, and VP and CFO Dominic Caruso attributed part of its success to American Association for the Study of Liver Diseases recommendation that it be used with Gilead's Sovaldi. Caruso said the recommendation “has been adopted by the medical community as a standard of care,” and that J&J's decision to revise the year's financial guidance by close to $1 billion is mostly because “Olysio is performing much better than our earlier expectations.” Caruso also noted that he believes most of the drug's sales are in tandem with Sovaldi prescriptions. Investor relations VP Louise Mehrotra said during the call that 20% of the Olysio prescriptions were inventory stocking, “so the majority of it was certainly flowing through out to the patients.”

The company also saw strong performance from established pharmaceuticals including Stelara, Invega Sustenna, Prezista and Velcade.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.